Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
Patent and Exclusivity Search Results from query on Appl No 022024 Product 002 in the OB_Rx list.
|Appl No||Prod No||Patent No||Patent
|N022024||002||5965584||Jun 19, 2016||Y||U - 973|
|N022024||002||6099859||Mar 20, 2018||Y|
|N022024||002||6166042||Jun 19, 2016||U - 973|
|N022024||002||6166043||Jun 19, 2016||U - 973|
|N022024||002||6172090||Jun 19, 2016||U - 973|
|N022024||002||6495162||Mar 20, 2018||Y|
|N022024||002||6790459||Mar 17, 2021||U - 974|
|N022024||002||6866866||Mar 17, 2021||Y|
|N022024||002||7785627||Jul 31, 2026||Y|
|N022024||002||7919116||Mar 20, 2018||U - 1120|
|N022024||002||7919116||Mar 20, 2018||U - 973|
|N022024||002||7959946||Jul 31, 2026||Y|
|N022024||002||8470368||Sep 19, 2023||Y|
|N022024||002||8475841||Mar 20, 2018||U - 973|
|N022024||002||8668931||Sep 19, 2023||Y|
|N022024||002||9060941||Sep 19, 2023||Y|
There is no unexpired exclusivity for this product.
- Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
- Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. These patents may not be flagged with respect to other claims which may apply.
View a list of all patent use codes
View a list of all exclusivity codes
FDA/Center for Drug Evaluation and Research
Office of Generic Drugs
Division of Labeling and Program Support
Orange Book Data - Monthly
Generic Drug Product Information & Patent Information - Daily
Orange Book Data Updated Through April 2016
Patent and Generic Drug Product Data Last Updated May 26, 2016